Introduction
Intestinal ultrasound (IUS) is a non-invasive modality for monitoring disease activity in inflammatory bowel disease (IBD). While widely used for long-term assessment, its utility in early response evaluation following biologic therapy initiation or modification remains underexplored.
Aims & Methods
This prospective study aimed to assess early ultrasonographic response at week 6 in ulcerative colitis (UC) and Crohn’s disease (CD) patients undergoing induction, dose escalation, or switching of biologic therapy. A total of 24 patients (mean age: 40.1 ± 12.8 years; 54.2% female) were included. Fourteen patients (58.3%) were initiating biologic treatment, 4 (16.7%) underwent dose escalation, and 6 (25%) were switched to another biologic agent. Biologic therapies included infliximab (70.8%), adalimumab (16.7%), and others (12.5%). IUS examination was performed at baseline and at week 6. The following parameters were assessed: bowel wall thickness (BWT), wall stratification, color doppler signal activity and mesenteric fat inflammation. IUS remission was defined as bowel wall thickness less than 3 mm and no color doppler signal. IUS improvement was defined as more than 25% decrease in bowel wall thickness without increase in color doppler signal. IUS activity assesment was performed at the same segment of the bowel at the 6th weeks.
Results
A total of 24 patients were included in the study, with a mean age of 40.1 ± 12.8 years; 13 (54.2%) were female. Seven patients (29.2%) had ulcerative colitis (UC), and 17 (70.8%) had Crohn’s disease (CD). Fourteen patients (58.3%) had newly initiated biologic therapy, 4 (16.7%) underwent dose escalation, and 6 (25%) were switched to a different biologic agent. Anti-TNF agents were used in 21 patients (87.5%), including infliximab in 17 (70.8%) and adalimumab in 4 (16.7%). The remaining 3 patients (12.5%) were treated with other biologic agents. At baseline, the most active intestinal segment on IUS was the terminal ileum in CD patients (9 patients, 52.9%) and the sigmoid colon in UC patients (4 patients, 57.1%) (p = 0.021). At week 6, 11 patients (45.8%) showed ultrasonographic improvement, 9 patients (37.5%) had no change, and 4 patients (16.7%) showed worsening. The baseline mean bowel wall thickness (BWT) of the most active segment was 5.5 ± 1.3 mm, which decreased to 4.4 ± 1.7 mm at week 6. A reduction in BWT was observed in 18 patients (75%), while an increase was seen in 6 patients (25%) (p = 0.002). In multivariate regression analysis, higher baseline bowel wall thickness was identified as an independent predictor of ultrasonographic improvement at week 6 (OR: 3.137; 95% CI: 1.005–9.790; p = 0.04). In patients who showed improvement, bowel wall thickness significantly decreased from baseline 6.2 ± 1.5 mm to 3.7 ± 1.6 mm at week 6 (to; p = 0.003), whereas in patients who worsened, an increase in wall thickness was observed (5.3 ± 1.0 mm to 6.7 ± 1.7 mm; p = 0.068). By disease group, 5 of the UC patients (71.4%) showed ultrasonographic improvement, 1 (14.3%) remained unchanged, and 1 (14.3%) worsened. Among CD patients, 6 (35.3%) showed improvement, 8 (47.1%) had no change, and 3 (17.6%) worsened. However, there was no statistically significant difference in response patterns between the UC and CD groups (p = 0.244).
Conclusion
Intestinal ultrasound at week 6 effectively detected early treatment response, with baseline bowel wall thickness emerging as a predictor of improvement. These results support its use in routine early monitoring of IBD patients on biologic therapy.
References
1. Calabrese E, Rispo A, Zorzi F, De Cristofaro E, Testa A, Costantino G, Viola A, Bezzio C, Ricci C, Prencipe S, Racchini C, Stefanelli G, Allocca M, Scotto di Santolo S, D'Auria MV, Balestrieri P, Ricchiuti A, Cappello M, Cavallaro F, Guarino AD, Maconi G, Spagnoli A, Monteleone G, Castiglione F. Ultrasonography Tight Control and Monitoring in Crohn's Disease During Different Biological Therapies: A Multicenter Study. Clin Gastroenterol Hepatol. 2022 Apr;20(4):e711-e722.
2. Paredes JM, Moreno N, Latorre P, Ripollés T, Martinez MJ, Vizuete J, Moreno-Osset E. Clinical Impact of Sonographic Transmural Healing After Anti-TNF Antibody Treatment in Patients with Crohn's Disease. Dig Dis Sci. 2019 Sep;64(9):2600-2606.